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Abstract
Background: The increase in the prevalence of insulin resistance-related metabolic syndrome, a
disorder that greatly increases the risk of diabetes, heart attack and stroke, is alarming. One of the
most frequent and early symptoms of metabolic syndrome is hypertriglyceridemia. We examined
the gender differences between various metabolic factors related to insulin resistance in elderly
non-diabetic men and postmenopausal women of comparable age suffering from
hypertriglyceridemia, and compared them with healthy subjects of equal age.
Results: The indexes of insulin resistance HOMA IR and QUICKI were significantly higher in both
hyperlipemic men and women than in controls; 95% confidence limits of hyperlipemic subjects did
not overlap with controls. In both normolipemic and hyperlipemic men and women serum leptin
correlated significantly with insulin resistance, while HDL-cholesterol correlated inversely with
HOMA-IR only in women (both normo- and hyperlipemic), and serum tumor necrosis factor 
(TNF) only in hyperlipemic women. According to results of multiple regression analysis with
HOMA-IR as a dependent variable, leptin played a significant role in determining insulin resistance
in both genders, but – aside from leptin – triglycerides, TNF and decreased HDL-cholesterol were
significant determinants in women, while body mass index and decreased HDL-cholesterol were
significant determinants in men. The coefficient of determination (R2) of HOMA IR by above
mentioned metabolic variables was in women above 60%, in men only about 40%.
Conclusion: The significant role of serum leptin in determination of insulin resistance in both
elderly men and postmenopausal women of equal age was confirmed. However, the study also
revealed significant gender differences : in women a strong influence of triglycerides, TNF and
decreased HDL-cholesterol, in men only a mild role of BMI and decreased HDL-cholesterol.
Background
In association with pandemic obesity the prevalence of
the insulin resistance-related metabolic syndrome is con-
stantly growing [1]. As a consequence of this fact, type 2
diabetes mellitus and cardiovascular mortality occurs in
much younger age groups [2]. A typical hyperlipemia,
consisting of an increase of serum triglycerides and a de-
crease of serum HDL-cholesterol, is a characteristic and an
early symptom of this syndrome [3].
With increasing age, body mass index (BMI) and adiposi-
ty, insulin sensitivity declines and the number of cardio-
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vascular risk factors increases in both genders [4–6]. It was
repeatedly demonstrated that plasma concentration of
leptin – a hormone produced mainly by adipose tissue –
is substantially higher in all age groups of women than in
men [7–10]. This may be caused by different size and/or
distribution of fat tissue compartments influenced by hor-
mones: estrogens stimulate, whereas testosterone inhibits
leptin secretion. In women subcutaneous fat mass prevails
– and during augmentation of overweight it increases –
while in men intra-abdominal fat mass prevails [11–13].
Subcutaneous fat in particular serves as a substantial
source of tumor necrosis factor  (TNF), which repre-
sents one of the factors that interfere with insulin signal
transduction into the cells [14–16]. Leptin, TNF and
some other factors are abundantly expressed in adipose
tissue and contribute to the insulin resistance that accom-
panies overweight and obesity. Leptin correlates positive-
ly with hyperinsulinemia, BMI, fat mass and
hypertriglyceridemia, respectively, and correlates inverse-
ly with HDL-cholesterol and lean body mass [17–25].
The incidence and mortality of ischemic heart disease and
of other consequences of atherosclerosis increases with
age in both genders, especially after the age of sixty. In pre-
menopausal women, however, the incidence of these dis-
orders is considerably less frequent than in men of
appropriate age. After the menopause the prevalence of
metabolic syndrome and cardiovascular mortality in
women gradually increases, attaining values comparable
to men at about the age of 70 [2,26]. Paradoxically, it
takes place at the time when serum leptin concentration
in women has relatively decreased [27,28].
The aim of this study was to analyze the interrelations be-
tween several metabolic variables and factors related to in-
sulin resistance in groups of both normal and
hyperlipemic postmenopausal women and men of appro-
priate age, and to attempt to elucidate the gender differ-
ences and some pathophysiologic mechanisms of these
differences. We compared homeostatic indexes of insulin
resistance HOMA IR and QUICKI, serum lipid and insulin
parameters, uric acid, leptin and TNF between groups of
subjects without apparent symptoms of metabolic syn-
drome, and groups showing mild hypertriglyceridemia
with decreased HDL-cholesterol. In addition, serum con-
centration of the heart fraction of fatty acid binding pro-
tein (hFATP) was explored as a factor that might reflect the
regulative role of PPAR gamma in lipid homeostasis
[29,30], and serum IgG anticardiolipin (ACL-IgG) was in-
vestigated as an indirect indicator of oxidized lipid frac-
tions related to atherosclerotic complications [31,32].
Methods
Subjects
The study was carried out on 70 out-patients of the Meta-
bolic Center at the hospital in Sternberk, Czech Republic.
From these, 40 patients (20 men and 20 women) were se-
lected with mild hyperlipidemia, i.e. with plasma triglyc-
eride concentration exceeding 2.0 mmol/l, total
cholesterol exceeding 6.0 mmol/l, LDL cholesterol ex-
ceeding 4.0 mmol/l, and with HDL cholesterol concentra-
tion in men under 1.0 mmol/l, and in women under 1.2
mmol/l. These groups were denominated as "hyperli-
pemic". Two other groups (10 men and 20 women) with
approximately normal serum values of these variables
were taken as "controls". The average age in men was 59.1
 10.6 y, and in women 59.4  10.1 y, respectively. The
differences between lipid parameters of hyperlipemic and
control groups were highly statistically significant, while
the age differences were insignificant (see Table 1). None
of the patients had clinically apparent diabetes mellitus,
but some of the hyperlipemic patients exerted impaired
glucose tolerance or impaired fasting glucose (values be-
tween 6.1 and 7.0 mmol/l, or between 6.1 and 7.8 mmol/
l, respectively). None of the patients was treated with in-
sulin, peroral antidiabetics or antihyperlipemic drugs;
some of them were treated with antihypertensive therapy.
No signs of major clinical or laboratory symptoms of oth-
er diseases were present in any group of the explored pa-
tients. Blood samples were obtained in the morning via a
venipuncture after overnight fasting. After clotting the se-
rum was separated and stored at -20 until used. An in-
formed consent was obtained from all probands.
Body mass indexes (BMI), defined as weight in kilograms
divided by the square of height in meters, were calculated.
Biochemical methods
Serum leptin concentrations were measured by a sand-
wich ELISA test kit (Human Leptin ELISA, BioVendor Lab-
oratory Medicine, Inc, Czech Republic). Its sensitivity
limit was 0.2 ng/ml, intraassay CV 6.1% at the level of 7.5
ng/m, inter-assay CV 8.5% at the level of 4.8 ng/ml. Te-
tramethylbenzidine was used as a substrate; quality con-
trols were human based. Several other hormones and
peptides were estimated by routine immunochemical
tests: insulin, C-peptide, TNF (IMMULITE, Diagnostic
Products Corporation, Los Angeles, CA, U.S.A.), proinsu-
lin intact (DAKO, Denmark), IgG anticardiolipin (ACL-
IgG, IMMCO Diagnostics, Buffalo, NY, U.S.A.) and heart
fatty acid binding protein (hFABP, Hbt HUMAN H-FABP,
HyCult Biotechnology, Uden, the Netherlands). Serum
concentration of glucose, total cholesterol, triglycerides,
HDL-cholesterol, LDL-cholesterol, Apoprotein B and uric
acid were measured on a ILAB-600 biochemical analyzer
(Instrumentation Laboratory, Lexington, Ma, U.S.A.) us-
ing BioVendor sets. All samples were processed and exam-Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/4
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ined according to principles of good laboratory practice
and under constant intralaboratory and external quality
control.
The homeostatic indexes of insulin resistance (HOMA IR
and QUICKI) were calculated according to the homeosta-
sis model of assessment [33–35] as follows:
HOMA IR = fasting insulin (U/ml) * fasting glucose
(mmol/l) / 22.5;
QUICKI = 1 / [log fasting insulin (U/ml) + log fasting
glucose (mg/100 ml)].
Statistics
Statistical analysis was performed using the Version 6
SAS/STAT software (SAS Institute, Inc., Cary, NC, U.S.A.).
The Shapiro-Wilks tests were used in testing the normality
of distribution. Some of the data obtained were not nor-
mally distributed. The statistical significance of differenc-
es between the means in the hyperlipemic and control
groups were evaluated using the unpaired Student's T-test
in the case of normal distribution of data sets, and using
the Kolmogorov-Smirnov test when at least in one of the
data sets the normal distribution was excluded. Spear-
man's rank-order correlation was used for correlation
analysis. Multiple regression analysis was performed us-
ing HOMA IR indexes of insulin resistance as dependent
variables, and other metabolic and hormonal factors (lip-
id parameters, BMI, leptin, TNF, hFABP, ACL-IgG) as in-
dependent variables. The so-called step-down regression
model was used to select dominant independent varia-
bles. Various four-member groups of independent (ex-
planatory) variables were used for the analysis and the
non-zero intercept was taken into account. The independ-
ent variables were then dropped, one at a time; at each
stage one variable making the least contribution to the de-
pendent variable (i.e. that showed the least p-value in the
test of the regression coefficient being zero) was excluded.
The coefficient of determination R2, which can be viewed
as a percentage explaining the total variance, was simulta-
neously monitored. A great drop in R2 after excluding
some independent variable enabled selection of those in-
dependent variables that could be thought to be the most
important determinants of the dependent variable.
Results
Table 1 demonstrates mean parameters in individual
groups of subjects matched according to sex, lipid param-
eters and age. While the age of all four groups did not dif-
fer substantially, the concentrations of total serum
cholesterol, triglycerides, HDL-cholesterol and LDL-cho-
lesterol differ very significantly in both male and female
hyperlipemic groups as compared with controls. In addi-
tion, the concentration of triglycerides in control women
was significantly higher than in control men, the concen-
tration of triglycerides in hyperlipemic women was lower
than in hyperlipemic men, and the concentration of HDL-
cholesterol in hyperlipemic women was very significantly
higher when compared with hyperlipemic men.
Table 2 shows the values of other metabolic and insulin
parameters, factors related to insulin resistance and index-
es of insulin resistance, respectively. Body mass indexes
and uric acid concentration were significantly higher in
hyperlipemic men as compared to controls, but not in hy-
perlipemic women. Uric acid concentration was substan-
tially lower in hyperlipemic women than in hyperlipemic
men. Plasma concentrations of glycemia, insulin and in-
tact proinsulin were significantly higher in both hyperli-
Table 1: Main characteristics that served in selection of groups of patients under study
MEN WOMEN
Controls N = 10 
Mean  SD
Hyperlipemic patients 
N = 20 Mean  SD
p Controls N = 20 
Mean  SD
Hyperlipemic patients 
N = 20 Mean  SD
p
Age (years) 60.3  11.0 58.6  10.4 0.69 56.9  13.0 62.0  7.36 0.15
Cholesterol (mmol/l) 5.07  1.06 6.62  0.82 0.0001 5.15  0.70 6.92  1.01 0.0001
Triglycerides (mmol/l) 1.11  0.44 3.52  1.38 0.0001 1.42  0.47 * 2.72  0.92* 0.0001 KS
HDL-chol. (mmol/l) 1.43  0.39 0.96  0.24 0.0003 1.50  0.21 1.21  0.21*** 0.0001
LDL-chol. (mmol/l) 3.08  0.83 4.38  1.06 0.0047 3.21  0.71 4.74  1.02 0.0001
Statistical significance between control and hyperlipemic groups was tested using the unpaired Student's T-test in the case of normal distribution of 
compared data sets, and using Kolmogorov-Smirnov's test when at least in one of the data sets compared the normal distribution was excluded 
(marked with KS). The significant p values are denoted by thick underlined numbers. With asterisks statistically significant differences between con-
trols and hypelipemic patients of different gender are denoted (*, **, *** = p < 0,05, 0,01 and 0,001, respectively).Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/4
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pemic men and women as compared with controls of
identical gender, while the concentration of leptin in-
creased only in hyperlipemic men. However, serum leptin
concentrations of both control and hyperlipemic women
were significantly higher than in corresponding groups of
men. Serum concentrations of TNF, hFABP and ACL-IgG
in hyperlipemic groups of both men and women were not
significantly different from control groups. On the other
hand, the indexes of insulin resistance HOMA IR and
QUICKI differed very significantly in hyperlipemic groups
of both men and women as compared with corresponding
control groups, more distinctly in women.
From Fig. 1, presenting 95% confidence limits of insulin
resistance indexes HOMA IR and QUICKI, we concluded
that in groups of hyperlipemic patients of both genders
the insulin resistance was substantially higher than in
control groups; the groups did not overlap each other.
In Table 3 the results of Spearman's correlations between
insulin resistance index HOMA IR and various metabolic
parameters are presented. In the control group of men,
positive significant correlation between HOMA IR and se-
rum leptin concentration, and inverse significant correla-
tion between HOMA IR and ACL IgG, respectively, were
found. In the control group of women, the significance of
Spearman's correlation between HOMA IR and leptin was
more expressive; inverse correlation between HOMA IR
and HDL-cholesterol was also present.
In the hyperlipemic group of men, the significance of the
correlation between HOMA IR was more expressive in re-
lation to the control group, and no significant correlation
between HOMA IR and ACL IgG was found. In the hyper-
lipemic group of women, however, the significance of
Spearman's correlation between HOMA IR and serum lep-
tin concentration weakened, the inverse correlation be-
tween HOMA IR and HDL-cholesterol remained
Table 2: Detailed characteristics of the subjects under study
MEN WOMEN
Controls N = 10 
Mean  SD
Hyperlipemic patients 
N = 20 Mean  SD
p Controls N = 20 
Mean  SD
Hyperlipemic patients 
N = 20 Mean  SD
p
BMI 25.91  3.58 28.51  2.60 0.030 25.36  3.72 26.73  3.59 0.24
HOMA IR 1.685  0.771 3.137  1.419 0.002KS 1.717  0.893 2.694  1.011 0.001KS
QUICKI 0,3596  0,0263 0,3266  0,0185 0,002 0,3603  0,0281 0,3332  0,0192 0,0007
Uric acid (mmol/l) 270.5  65.4 379.9  84.2 0.003 236.1  67.0 270.8  58.9*** 0.13
Glycemia (mmol/l) 5.31  0.53 6.11  0.95 0.029KS 5.26  0.42 5.85  0.70 0.0027
Insulin (mIU/l) 6.96  2.80 11.43  4.50 0.016KS 7.33  3.80 10.27  3.52 0.034KS
Proinsulin intact 
(pmol/l)
2.68  1.15 5.51  2.75 0.012KS 2.51  1.76 4.49  3.11 0.034KS
C-peptide (nmol/l) 0.66  0.31 1.11  0.39 0.0148 0.75  0.35 0.92  0.34 0.22KS
Leptin (ng/ml) 3.07  3.38 6.21  3.78 0.012KS 16.06  13*** 17.79  5.9** 0.17KS
TNF (pg/ml) 14.2  4.15 11.52  2.77 0.063KS 11.65  6.80 12.73  9.15 0.43KS
hFABP (pg/ml) 3.86  2.47 4.53  1.97 0.46 3.09  1.80 3.79  2.00 0.41KS
ACL-IgG (IU/ml) 13.08  6.75 19.63  16.9 0.57KS 12.28  6.38 16.35  16.8 0.99KS
BMI = body mass index, HOMA IR and QUICKI = homeostatic indexes of insulin resistance (see Methods), TNF = tumor necrosis factor , 
hFABP = heart fraction of fatty acid binding protein, ACL-IgG = IgG anticardiolipin. Other designations are the same as in Table 1.
Figure 1
Schematic presentation of 95% confidence limits of insulin
resistance indexes HOMA IR and QUICKI in groups of con-
trol and hyperlipemic women and men.   = Controls
(women)   = Controls(men)   = Hyperlipemic
women   = Hyperlipemic men
Figure 1 
HOMA IR                   QUICKI
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approximately unchanged, and a positive correlation be-
tween HOMA IR and serum concentration of TNF ap-
peared.
Table 4 shows results of multiple regression analysis,
when data from both control and hyperlipemic groups of
each gender were judged together. HOMA IR was consid-
ered as a dependent variable and differently changed con-
stellations of metabolic and other factors were taken as
independent variables.
In men, BMI and leptin seemed to play a main role in in-
fluencing the insulin resistance index HOMA IR, while
TGL, ACL IgG and LDL-cholesterol didn't play any signif-
icant role (see left columns of Table 4). The decreasing of
HDL-cholesterol concentration may also have some influ-
ence (see a significant drop of R2 after exclusion of this
factor in Table 4A, 4B). But in the presence of leptin in the
group of independent factors, the drop of R2 after exclu-
sion of HDL-cholesterol from these factors was minimal
(see Table 4C). On the other hand, after the exclusion of
TNF from the group of independent variables (see Table
4B, 4D) the value of R2 has unexpectedly risen, which
could reflect the interference of TNF with factors increas-
ing the insulin resistance.
In women (see right columns of Table 4), the maximal
values of R2 were achieved with combination of inde-
pendent variables containing TGL, leptin and HDL-cho-
lesterol (about 60% influence on HOMA IR! – see Table
4A, 4B, 4C). TNF seemed to play quite a different role
than in men: after exclusion of this factor from the group
of independent factors R2significantly decreased (see Ta-
ble 4B, 4D). In contrast to men, the role of BMI seemed to
be minimal. As in men, the role of ACL IgG and LDL-cho-
lesterol in influencing HOMA IR was negligible, but in
contrast to men, hFABP might play a certain role in this
process (see Table 4D).
Table 3: Spearman's correlations between HOMA IR and various metabolic factors studied
CONTROLS
MEN (n = 10) BMI TGL HDL LDL Leptin TNF ACL IgG FABP
HOMA IR Sk = 0,248 Sk = 0,515 Sk = 0,006 Sk = 0,428 Sk = 0,658 Sk = -0,119 Sk = -0,714 Sk = -0,405
p = 0,49 p = 0,13 p = 0,85 p = 0,29 p = 0,038 p = 0,778 p = 0,046 p = 0,319
WOMEN (n = 20) BMI TGL HDL LDL Leptin TNF ACL IgG FABP
HOMA IR Sk = 0,354 Sk = 0,157 Sk = -0,499 Sk = 0,393 Sk = 0,826 Sk = 0,225 Sk = 0,296 Sk = 0,134
p = 0,13 p = 0,51 p = 0,025 p = 0,13 p = 0,0001 p = 0,459 p = 0,325 p = 0.660
HYPERLIPEMIC SUBJECTS
MEN (n = 20) BMI TGL HDL LDL Leptin TNF ACL IgG FABP
HOMA IR Sk = 0,358 Sk = -0,278 Sk = -0,180 Sk = -0,057 Sk = 0,574 Sk = -0,235 Sk = 0,173 Sk = 0,014
p = 0,12 P = 0,24 p = 0,45 p = 0,99 p = 0,008 p = 0,317 p = 0,466 p = 0,952
WOMEN (n = 20) BMI TGL HDL LDL Leptin TNF ACL IgG FABP
HOMA IR Sk = 0,308 Sk = 0,334 Sk = -0,554 Sk = -0,111 Sk = 0,471 Sk = 0,447 Sk = 0,079 Sk = 0,224
p = 0,19 p = 0,15 p = 0,011 p = 0,85 p = 0,036 p = 0,048 p = 0,740 p = 0.342
Sk = Spearman's correlation index. Significant values (p < 0,05) are denoted with thick numbers.Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/4
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Table 4: Multiple regression analysis of data from men and women (controls and tests).
A MEN WOMEN
Interc HDL TGL LDL BMI R2 Interc HDL TGL LDL BMI R2
HOMA IR Par. -0,27 -1,07 0,11 -0,06 0,19 0,29 2,74 -1,95 0,31 0,02 0,05 0,56
T = 0 0,91 0,04 0,55 0,79 0,03 0,11 0,006 0,09 0,87 0,19
Par. -0,75 -1,68 -0,07 0,19 0,32 2,62 -1,83 0,34 0,05 0,52
T = 0 0,73 0,03 0,68 0,016 0,09 0,007 0,04 0,16
Par. -0,84 -1,52 0,19 0,32 4,11 -1,98 0,38 0,49
T = 0 0,69 0,02 0,015 0,0007 0,003 0,02
Par. -2,54 0,18 0,17 6,09 -2,86 0,42
T = 0 0,25 0,02 0,0001 0,0001
B MEN WOMEN
Interc BMI TNF

HDL TGL R2 Interc BMI TNF HDL TGL R2
HOMA IR Par. 0,20 0,17 -0,04 -1,46 -0,07 0,27 0,78 0,05 0,05 -0,95 0,41 0,64
T = 0 0,94 0,055 0,62 0,09 0,70 0,62 0,17 0,0008 0,14 0,008
Par. 0,14 0,16 -0,04 -1,29 0,27 2,32 0,05 1,15 0,45 0,62
T = 0 0,95 0,054 0,58 0,08 0,04 0,0013 0,07 0,004
Par. -0,84 0,18 -1052 0,32 0,36 0,06 0,61 0,58
T = 0 0,69 0,015 0,02 0,31 0,0002 0,0001
Par. -2,55 0,19 0,17 0,79 0,68 0,36
T = 0 0,25 0,02 0,02 0,0001
C MEN WOMEN
Interc BMI Lep-
tin
HDL TGL R2 Interc BMI Leptin HDL TGL R2
HOMA IR Par. 0,54 0,09 0,13 -1,07 -0,03 0,39 1,90 0,01 0,03 -1,14 0,46 0,61
T = 0 0,81 0,31 0,10 0,19 0,85 0,18 0,73 0,007 0,077 0,0056
Par. 0,52 0,09 0,13 -0,99 0,39 2,18 0,04 -1,14 0,47 0,61
T = 0 0,81 0,30 0,08 0,14 0,06 0,002 0,07 0,003
Par. 2,62 0,18 -0,80 0,37 0,13 0,05 0,64 0,58
T = 0 0,007 0,005 0,22 0,68 0,0001 0,0001
Par. 1,59 0,20 0,33 0,79 0,68 0,37
T = 0 0,0001 0,000
9
0,02 0,0001
D MEN WOMEN
Interc Leptin TNF

FABP ACL R2 Interc Leptin TNF FABP ACL R2Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/4
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Generally, the insulin resistance (represented by HOMA
IR) was in men much less influenced by metabolic varia-
bles than in women; while in women in some combina-
tions of dependent variables R2 reached 64 %, in men the
maximal value of R2 was only 39 %.
Discussion
In our previous paper [36], the mean value of HOMA IR
in healthy subjects of both genders and of age comparable
with our controls was 1.57  0.87, and the mean value of
index QUICKI 0.366  0.029, respectively. These values,
as well as the 95 % confidence limits, correspond to val-
ues found in controls in this study.
In accordance with many previous papers, serum concen-
trations of leptin in women (both control and hyperli-
pemic) were substantially higher than in men. In the
control group of women the correlation between leptin
and HOMA IR was highly significant. However, in hyper-
lipemic women the significance of this correlation less-
ened, because HOMA IR increased considerably (and
significantly) but serum concentration of leptin only
slightly (insignificantly). In men the significance of corre-
lations between serum leptin and HOMA IR was high and
approximately the same in both the control and hyperli-
pemic groups, because the values of HOMA IR as well as
serum leptin have nearly doubled in hyperlipemic in rela-
tion to control groups. In non-hyperlipemic postmeno-
pausal women the high concentration of serum leptin was
not associated with higher insulin resistance: HOMA IR
did not differ substantially from men. A significant in-
crease of insulin resistance in hyperlipemic women was
associated by only slight and insignificant increase of lep-
tin concentration. According to Spearman's correlations,
an increase of serum TNF and/or a decrease of HDL-cho-
lesterol might also play a distinct role in this respect. (see
Table 3). In contrast to women, in hyperlipemic men the
increase of insulin resistance index was approximately
proportional with the increase of leptin concentration.
Multiple regression analysis affirmed the importance of
leptin serum in increasing of insulin resistance in both
genders. In men, only BMI and HDL-cholesterol from oth-
er factors studied seemed to play a certain role, but the
maximal values of influencing HOMA IR reached only
39%, with leptin and BMI being the more important fac-
tors. On the other hand, in women the maximal determi-
nation of HOMA IR as high as 60% was registered in
combination of serum leptin, TGL and decreased HDL-
cholesterol as independent factors; the role of BMI was in-
significant.
It is not known how leptin is regulated. A strong correla-
tion between plasma leptin and fasting insulin undoubt-
edly exists, but hyperleptinemia in both obese and lean
humans is not likely the result of hyperinsulinemia [37].
A relationship between leptin and insulin dependent on
sex or BMI was reported, but relationship between triglyc-
eride concentrations and leptin was independent of sex,
BMI, and insulin [18,24]. Hyperleptinemia, as an early
sign of obesity, was closely linked to subcutaneous fat
mass [39,40]. Percentage of body fat has been shown to be
the strongest predictor of leptin levels even in lean women
[41]. Leptin was highly correlated with percentage of body
fat and with fat mass in adults irrespective of gender and
age; however, the mean determinant of leptin plasma con-
centration in men and postmenopausal women was BMI,
while in premenopausal women it was only the fat mass
[42]. These findings contrast with our results showing
minimal influence of BMI on HOMA IR in postmenopau-
sal women.
All factors mentioned are connected with fat tissue: leptin
and TNF are directly produced chiefly by adipocytes,
BMI growth is obviously accompanied by fat mass in-
crease, and the typical hypertriglyceridemia associated
with a decrease of HDL-cholesterol goes along with obes-
ity and fat mass growth. The gender differences in circulat-
ing leptin were best explained by percentage of body fat
HOMA IR Par. 2,48 0,17 -0,04 -0,05 0,004 0,29 0,46 0,04 0,05 0,17 0,002 0,44
T = 0 0,07 0,02 0,57 0,70 0,82 0,38 0,014 0,018 0,028 0,82
Par. 2,49 0,18 -0,04 -0,04 0,29 0,52 0,04 0,04 0,17 0,44
T = 0 0,06 0,010 0,56 0,72 0,25 0,011 0,016 0,02
Par. 2,27 0,18 -0,04 0,28 1,25 0,04 0,04 0,34
T = 0 0,04 0,009 0,58 0,0012 0,029 0,03
Par. 1,59 0,20 0,33 1,36 0,05 0,26
T = 0 0,0001 0,0009 0,0001 0,0007
HOMA IR was taken as dependent variable, various combinations of metabolic factors studied as independent variables. Par. = parameter (slope, 
regression coefficient). T = 0 = p-value in testing the regression coefficient being zero. Interc = intercept. R2 = coefficient of determination 
(expressing the percentage of determination of dependent variable by independent variables). A step-down regression model was used to disclose 
dominant independent variables (see Statistics). R2 of dominant independent variables and statistically significant regression coefficients are 
denoted by thick numbers.
Table 4: Multiple regression analysis of data from men and women (controls and tests). (Continued)Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/4
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and – inversely – by lean body mass [25]. In both genders
the intra-abdominal fat correlated with insulin resistance,
while the subcutaneous fat correlated with circulating lep-
tin [11,12]. In men obesity led to a prevalent increase of
intra-abdominal fat, while in women of subcutaneous fat
[13]. Influences of different compartments of adipose tis-
sues could elucidate the variability of correlations be-
tween insulin resistance and high leptin concentrations in
lean and obese subjects of both genders [43]. In our non-
hyperlipemic postmenopausal women the content of sub-
cutaneous fat mass might be higher than in non-hyperli-
pemic men of appropriate age, which indicated a higher
serum concentration of leptin. However, the insulin re-
sistance – related to intra-abdominal fat mass – did not
differ from men. The significant increase of insulin resist-
ance and leptin concentration in hyperlipemic men might
reflect the growing content of both subcutaneous and in-
tra-abdominal fat mass (see the significant increase of
BMI). In hyperlipemic women the significant increase of
insulin resistance accompanying only minimal insignifi-
cant increase of leptin could be caused by prevalent grow-
ing of intra-abdominal fat mass.
In elderly postmenopausal women, an association be-
tween leptin and plasma lipoprotein concentration was
found which depended on adiposity [17], and inverse cor-
relations between serum leptin and HDL-cholesterol were
described [44]. In our study, insulin resistance in women
seemed to be more notably than in men influenced by li-
pid disorders, i.e. positively by serum triglycerides and in-
versely by HDL-cholesterol. These findings might be
important in considering the concept of treatment of in-
sulin resistance-related disorders in postmenopausal
women.
The significant role of TNF in insulin resistance, caused
by inhibiting the transduction of insulin signaling and by
down-regulation of glucose transporter GLUT-4 and insu-
lin receptor substrate-1, has been repeatedly confirmed
[45–48]. Our results supported these findings unambigu-
ously only in women, while in men TNF seemed para-
doxically to interfere with other factors – mainly BMI and
leptin – in influencing insulin resistance, thus playing a
quite different role. Previously it was found [46] that cor-
relation between serum TNF on the one side, and insu-
lin, HOMA IR, serum triglycerids, respectively, on the
other side, was substantially more significant in women
than in men. Serum concentration of TNF in patients
with type 2 diabetes of both genders correlated only with
the quantity of intra-abdominal fat compartment [50].
Visceral obesity correlated with plasmatic aldosterone and
with insulin resistance only in premenopausal women,
but not in men [51].
From all these data we might support our above men-
tioned conclusion – that rising of insulin resistance in hy-
perlipemic women was associated with an increase of
intra-abdominal fat, because this fat mass in particular is
a source of TNF, which interfered with insulin sensitivity
only in women. We came to this conclusion irrespective of
the finding that the increase of serum TNF in hyperli-
pemic women was statistically insignificant; results of
Spearman's correlation (Table 3) and multiple regression
analysis confirm a distinct role of this factor. In hyperli-
pemic men not only the serum concentration of TNF has
decreased instead of increasing, but according to multiple
regression analysis it played a quite different role in influ-
encing insulin sensitivity, interfering with factors that de-
termined insulin resistance (leptin and BMI).
In the control group of men IgG anticardiolipin was in-
versely correlated to HOMA IR. The significance of this
finding is not clear. These antibodies indicate vascular and
thrombotic complications and oxidative modification of
lipoproteins [52,53] and may represent an increased risk
of atherogenic and inflammatory complications. In this
case, however, their growing might be connected with an
increase in insulin sensitivity. Anyway, ACL IgG evidently
did not participate significantly in influencing the in-
crease of insulin resistance associated with hyperlipi-
demia, although other anti-cardiolipin correlations could
be masked by the relatively large inter-individual varia-
tions in this parameter.
Neither serum concentration of hFABP, a factor ensuring
transmembrane transport and oxidative metabolisation
of long-chain fatty acids [54,55], was significantly
changed in hyperlipemic and insulin resistant subjects of
both genders. This factor was very weakly associated only
with HOMA IR in women (see Table 4D), indicating that
enhanced metabolisation of fatty acids in cells might to
some degree contribute to insulin resistance.
Conclusions
In postmenopausal women as well as in men of approxi-
mately equal age serum leptin plays a significant role as an
important determinant of insulin resistance. In addition
to this factor, in women the grade of insulin resistance is
very considerably influenced by serum triglycerides, tu-
mor necrosis factor alpha, and by decreased concentration
of HDL-cholesterol, while in men only a mild influence of
BMI and decreased HDL-cholesterol is observed. These
findings are explained as a consequence of gender-related
differences in adipose tissue composition and/or distribu-
tion in both normal-weight and over-weight subjects and
should be taken into account in treatment of patients with
metabolic risk factors of cardiovascular diseases.Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/4
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List of abbreviations
HDL-Cholesterol = high-density cholesterol
LDL-cholesterol = low-density cholesterol
HOMA IR = Homeostasis Assessment of Insulin Resist-
ance
= fasting insulin (U/ml) * fasting glucose (mmol/l) /
22,5
QUICKI = 1 / [log fasting insulin (U/ml) + log fasting
glucose (mg/100 ml) ]
TNF = tumor necrosis factor alpha
BMI = body mass index
R2 = coefficient of determination
hFABP = heart fatty acid binding protein
ACL-IgG = IgG fraction of anticardiolipin
TGL = triglycerides
GLUT-4 = glucose transporter-4
PPAR = Peroxisome Proliferator-Associated Receptor
gamma
CV = coefficient of variation
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